Cellular Senescence Network: Technology Development and Application in Murine Systems (UG3/UH3 Clinical Trial Not Allowed)

The summary for the Cellular Senescence Network: Technology Development and Application in Murine Systems (UG3/UH3 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Cellular Senescence Network: Technology Development and Application in Murine Systems (UG3/UH3 Clinical Trial Not Allowed): The purpose of this FOA is to solicit novel analytics and technologies to identify and map senescent cells in murine tissues at high resolution. This FOA supports the accelerated proof-of-principle demonstration of promising tools, techniques and methods that can be integrated, scaled, and applied to multiple murine tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in murine tissues. The subsequent UH3 phase is to support initial validation in multiple optimization and scale-up, generation of production level data and the application of the technology to describe cellular senescence in a mouse life course situation (for example development or lifespan). Investigators responding to this FOA must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability of funds.

Federal Grant Title:	Cellular Senescence Network: Technology Development and Application in Murine Systems (UG3/UH3 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-RM-22-005
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.310
CFDA Descriptions:	Information not provided
Current Application Deadline:	January 19th, 2022
Original Application Deadline:	January 19th, 2022
Posted Date:	October 28th, 2021
Creation Date:	October 28th, 2021
Archive Date:	February 24th, 2022
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	October 28th, 2021

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-005.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial No...; • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...; • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional); • NIH Directors Early Independence Awards (DP5 Clinical Trial Optional); • NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional); • Using Metabolomics to Investigate Biological Pathways and Networks (R01); • Assay Development for High Throughput Molecular Screening (R21); • Membrane Protein Production and Structure Determination (R01)
More Grants from the National Institutes of Health: • Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed); • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...; • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...; • Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required); • Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans...